At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 335 enrolled
Drug / intervention
Blood drawprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 4, Open-label Study to Evaluate Persistence of the Antibody Response Elicited by Prevenar in Healthy Children in China Who Have Been Previously Immunized With a 4-dose Series of a Pneumococcal Conjugate Vaccine During Infancy in Study 0887x-101518
In Brief
A Phase 4 clinical trial evaluating Blood draw for Pneumococcal Disease. Completed, enrolled 335 participants across 10 sites.
Detailed Summary
In 2005, Wyeth conducted study 0887X-101518 (NCT00488826) in which Chinese infants received either Prevenar alone (Group 1), Prevenar given with a Diphtheria, Tetanus and acellular Pertussis (DTaP) vaccine (Group 2) or DTaP alone (Group 3). This follow up study (at least 3 years after the last vaccination) will assess the antibody concentrations in children who previously completed Wyeth study 0887X-101518.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPneumococcal Disease
CountriesChina
Collaborators--
Timeline
Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartNov 2010
First PostedFeb 2011
Primary CompletionMar 2011
TodayJul 2026
First PostedFeb 17, 2011
Enrollment StartNov 1, 2010
Primary CompletionMar 1, 2011
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 15.4 years ago
Interventions
Blood drawprocedure
One 5mL blood draw for immunogenicity at least 3 years post completion of clinical study 0887X-101518.